Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2019 · 10-Q
Revenue—
Net Income-$969.08K-$969.08KN/M vs Q2 2018 EPS Diluted-$0.18-$0.18N/M vs Q2 2018 Operating Income-$1,136,976N/M Operating Cash Flowderived-$526,547N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end